drugset

drugset / Trial / NCT01911715

A Study to Explore the Routes of Elimination of MDV3100

NCT01911715 ↗

Phase 1 Completed 6 enrolled Astellas Pharma Europe B.V. Medivation, Inc. · collab

NaSingle-groupOpen-labelBasic science

Summary

A study to investigate the excretion routes of radio-labelled MDV3100.

Timeline

Start: 2011-04
Primary completion: 2011-07
Completion: 2011-07

Publications

Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt JS, Beddo V, de Vries M, Mordenti J. Clinical Pharmacokinetic Studies of Enzalutamide. Clin Pharmacokinet. 2015 Oct;54(10):1043-55. doi: 10.1007/s40262-015-0271-5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Enzalutamide	Other / unclassified	160 mg	Oral

Indications

No indication recorded.